ArticleTranslational cancer research2021
Diagnostic significance of a color Doppler ultrasound combined with serum CXCL16 and E-cad in cervical cancer.
Article in Translational cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 citations in OpenAlex.
- Evaluating Performance of Transvaginal Doppler Parameters in Differentiating Cervical Neoplastic Severity.Diagnostics (Basel, Switzerland) · 2026Article
- Lycorine upregulates the expression of RMB10, promotes apoptosis and inhibits the proliferation and migration of cervical cancer cells.International journal of molecular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of effective non-invasive diagnostic markers in the early stage of cervical cancer is lacking currently. This study sought to investigate the value of color Doppler ultrasound combined with serum CXC chemokine ligand-16 (CXCL16) and epithelial cadherin (E-cad) levels in diagnosing cervical cancer.
methodsTwo hundreds cervical cancer patients admitted in our hospital between May 2018 and April 2020 were selected as the observation group. The control group included 100 healthy participants. The ultrasound parameters, and the serum CXCL16 and E-cad levels between the two groups and patients at different pathological stages were compared. The correlations between disease progress and ultrasound and serological indexes were analyzed. The diagnostic efficiency of an ultrasound and measures of serum CXCL16 and E-cad levels were compared as well.
resultsThe peak systolic velocity (PSV) of the observation group was significantly higher than that of the control group (P<0.05). In case of the resistance index (RI), the results were the opposite to the PSV (P<0.05). The PSV (P<0.05) and RI (P<0.05) were significantly different among different pathological stages. The serum CXCL16 (P<0.05) and E-cad (P<0.05) levels of participants in the observation group were significantly higher than those of patients in the control group. A pairwise comparison showed that the serum CXCL16 and E-cad levels increased significantly as the pathological stages of the cancer progressed. The diagnosis and disease progression of cervical cancer were positively correlated with PSV, CXCL16, and E-cad levels, and negatively correlated with the RI. Combining an ultrasound diagnosis with serum CXCL16 and E-cad levels had significantly higher diagnostic sensitivity than that of any individual indicator in patients with cervical cancer. The curve analysis showed that the cut-off values of PSV, the RI, CXCL16 and E-cad were 14.25, 0.50, 40.15 ng/mL and 85.36 pmmol/L, respectively.
conclusionsThe sensitivity of color Doppler ultrasound combined with serum CXCL16 and E-cad levels in the diagnosis of cervical cancer is high. Thus, it is recommended that it be used in clinics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.